The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4): A single-center, single-arm, open-label, phase 3 trial

BACKGROUND: Cost, adverse events, and long treatment duration can be significant obstacles in treating hepatitis C virus (HCV)-infected individuals. Shortening the treatment regimen can minimize these barriers, thereby enhancing adherence and increasing medication availability to more patients. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: AlEid, Ahmad, Al Balkhi, Areej, Qutub, Adel, Abbarh, Shahem, AlLehibi, Abed, Almtawa, Abdullah, Al Otaibi, Nawwaf, AlGhamdi, Ahmed, AlGhamdi, Adel, Alamr, Abdulrahman, Ahmad, Shameem, Al Sayari, Khalid, Al Ibrahim, Bashaar, AlKhathlan, Abdullah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212120/
https://www.ncbi.nlm.nih.gov/pubmed/35142658
http://dx.doi.org/10.4103/sjg.sjg_374_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212120/
https://www.ncbi.nlm.nih.gov/pubmed/35142658
http://dx.doi.org/10.4103/sjg.sjg_374_21

Ejemplares similares